Premium
Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin‐28B genotype
Author(s) -
Thompson Alexander J.,
Muir Andrew J.,
Sulkowski Mark S.,
Patel Keyur,
Tillmann Hans L.,
Clark Paul J.,
Naggie Susanna,
Fellay Jacques,
Ge Dongliang,
McCarthy Jeanette J.,
Goldstein David B.,
McHutchison John G.
Publication year - 2010
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.23826
Subject(s) - ribavirin , telaprevir , pegylated interferon , interleukin 28b , medicine , genotype , hepatitis c virus , hepatitis c , alpha interferon , population , immunology , virology , gastroenterology , interferon , virus , biology , genetics , gene , environmental health